Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias.

Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, Adélaïde J, Olschwang S, Xerri L, Vey N, Chaffanet M, Birnbaum D, Mozziconacci MJ.

Leukemia. 2010 Feb;24(2):469-73. doi: 10.1038/leu.2009.218. Epub 2009 Oct 29. No abstract available.

PMID:
19865112
2.

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.

Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, Nezri M, Tadrist Z, Olschwang S, Vey N, Birnbaum D, Gelsi-Boyer V, Mozziconacci MJ.

BMC Cancer. 2010 Aug 2;10:401. doi: 10.1186/1471-2407-10-401.

3.

Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome.

Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, Benthaus T, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Bohlander SK, Spiekermann K.

J Clin Oncol. 2010 Feb 1;28(4):570-7. doi: 10.1200/JCO.2008.21.6010. Epub 2009 Dec 28.

PMID:
20038735
4.

Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations.

Boonthimat C, Thongnoppakhun W, Auewarakul CU.

Haematologica. 2008 Oct;93(10):1565-9. doi: 10.3324/haematol.12937. Epub 2008 Jul 18.

5.

Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.

Devillier R, Gelsi-Boyer V, Brecqueville M, Carbuccia N, Murati A, Vey N, Birnbaum D, Mozziconacci MJ.

Am J Hematol. 2012 Jul;87(7):659-62. doi: 10.1002/ajh.23211. Epub 2012 Apr 25.

6.

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.

Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Göhring G, Schlegelberger B, Döhner K, Ottmann O, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Döhner H, Heil G, Ganser A, Krauter J.

J Clin Oncol. 2010 Feb 1;28(4):578-85. doi: 10.1200/JCO.2009.23.0342. Epub 2009 Dec 28.

PMID:
20038731
7.

FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.

Bains A, Luthra R, Medeiros LJ, Zuo Z.

Am J Clin Pathol. 2011 Jan;135(1):62-9. doi: 10.1309/AJCPEI9XU8PYBCIO.

PMID:
21173125
8.

The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication.

Micol JB, Boissel N, Renneville A, Castaigne S, Gardin C, Preudhomme C, Dombret H.

Blood. 2009 Nov 12;114(20):4601-2; author reply 4602-3. doi: 10.1182/blood-2009-07-230995. No abstract available.

9.

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).

Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein HU, Vignetti M, Piciocchi A, Fazi P, Martelli MP, Vitale A, Pileri S, Miesner M, Santucci A, Haferlach C, Mandelli F, Haferlach T.

Blood. 2010 May 6;115(18):3776-86. doi: 10.1182/blood-2009-08-240457. Epub 2010 Mar 4. Erratum in: Blood. 2010 Aug 12;116(6):1017.

10.

Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.

Wang ES, Sait SN, Gold D, Mashtare T, Starostik P, Ford LA, Wetzler M, Nowak NJ, Deeb G.

Cancer Genet Cytogenet. 2010 Oct 15;202(2):101-7. doi: 10.1016/j.cancergencyto.2010.07.117.

PMID:
20875872
11.

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE.

J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3.

PMID:
20439648
12.

Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype.

Bacher U, Haferlach T, Alpermann T, Kern W, Schnittger S, Haferlach C.

Leukemia. 2013 Feb;27(2):496-500. doi: 10.1038/leu.2012.200. Epub 2012 Jul 17. No abstract available.

PMID:
22858909
13.

Clinical implications of non-A-type NPM1 and FLT3 mutations in patients with normal karyotype acute myeloid leukemia.

Park BG, Chi HS, Park SJ, Min SK, Jang S, Park CJ, Kim DY, Lee JH, Lee JH, Lee KH.

Acta Haematol. 2012;127(2):63-71. doi: 10.1159/000331509. Epub 2011 Nov 18.

14.

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.

Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann HE, Kreuzer KA, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T.

Leukemia. 2013 Jan;27(1):82-91. doi: 10.1038/leu.2012.262. Epub 2012 Sep 11.

PMID:
23018865
15.

Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.

Haferlach T, Bacher U, Alpermann T, Haferlach C, Kern W, Schnittger S.

Leuk Res. 2012 Jan;36(1):51-8. doi: 10.1016/j.leukres.2011.04.026. Epub 2011 May 31.

PMID:
21621842
16.

Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD.

Hou HA, Chou WC, Lin LI, Chen CY, Tang JL, Tseng MH, Huang CF, Chiou RJ, Lee FY, Liu MC, Tien HF.

Leukemia. 2008 May;22(5):1075-8. Epub 2007 Nov 1. No abstract available.

PMID:
17972951
17.

Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.

How J, Sykes J, Gupta V, Yee KW, Schimmer AD, Schuh AC, Minden MD, Kamel-Reid S, Brandwein JM.

Cancer. 2012 Dec 15;118(24):6110-7. doi: 10.1002/cncr.27683. Epub 2012 Jun 26.

18.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
19.

A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics.

Huang Q, Chen W, Gaal KK, Slovak ML, Stein A, Weiss LM.

Br J Haematol. 2008 Jul;142(3):489-92. doi: 10.1111/j.1365-2141.2008.07205.x. Epub 2008 May 9. No abstract available.

PMID:
18477048
20.

Reversal of FLT3 mutational status and sustained expression of NPM1 mutation in paired presentation, and relapse samples in a patient with acute myeloid leukemia.

Radojkovic M, Tosic N, Colovic N, Ristic S, Pavlovic S, Colovic M.

Ann Clin Lab Sci. 2012 Spring;42(2):186-90.

PMID:
22585616

Supplemental Content

Support Center